Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21914652 | 0.78 | THRB (0.44) | — | |
| SCHEMBL21914658 | 0.75 | — | — | |
| SCHEMBL21914340 | 0.72 | PARP1 (0.36) | — | |
| SCHEMBL16790003 | 0.71 | — | — | |
| SCHEMBL5935841 | 0.71 | HTR2A (0.31) | — | |
| SCHEMBL16812698 | 0.71 | PARP1 (0.30) | — | |
| SCHEMBL21915013 | 0.67 | PBRM1 (0.40) | — | |
| SCHEMBL21915014 | 0.66 | PARP1 (0.34) | — | |
| SCHEMBL22536515 | 0.66 | PDK1 (0.41) | — | |
| SCHEMBL22536517 | 0.66 | PDK1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597399-B2 | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-03-24 | — | — | US | disclosed |
| EP-3381919-A1 | SUBSTITUTED TRIAZOLOPIPERAZINE PARP INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-10-03 | — | — | EP | disclosed |
| US-20180265516-A1 | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265516-A1 | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof | PARP1, PARP11, PARP2 | MEN1 1746/4885KMT2A 2021/4885 |
| US-10597399-B2 | Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof | PARP1, PARP11, PARP2 | MEN1 1841/4885KMT2A 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.